You are here: Industry Insights > Xencor

News List

Xencor, MD Anderson enter collaboration to develop novel T cell-engaging bispecific antibodies for potential treatment of cancer pharmaceutical-business-review
January 13, 2021
Xencor and The University of Texas MD Anderson Cancer Center announced a strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody therapeutics for the potential treatment of patients with cancer.
Xencor, Vir Biotechnology sign licensing deal for Covid-19 pharmaceutical-technology
March 27, 2020
Biopharmaceutical firm Xencor has entered into a technology licence agreement with Vir Biotechnology providing the latter with non-exclusive access to Xtend Fc technology.
Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program pharmafocusasia
April 03, 2019
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced it has entered into a research and license agreement in...
Xencor Announces Closing of Research Collaboration and License Agreement with Genentech pharmafocusasia
March 12, 2019
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer.
Turbulent times for Xencor as FDA slaps hold on AML bispecific fiercebiotech
February 22, 2019
Xencor didn’t have the best start to 2019—in January, its partner Novartis returned the rights to a bispecific antibody it had licensed as part of a 2016 deal worth up to $2.41 billion....
FDA halts Xencor’s study of XmAb14045 following deaths pharmaceutical-technology
February 22, 2019
California-based Xencor has announced the US Food and Drug Administration (FDA) has placed a partial clinical hold on its Phase I trial of its acute myeloid leukaemia drug XmAb14045 following the deaths of two participants....
Xencor Announces Board of Directors Appointment americanpharmaceuticalreview
November 10, 2018
Xencor announced the appointment of Ellen G. Feigal, M.D., to its board of directors. Dr. Feigal is currently a partner at NDA Partners, a strategy consulting firm, where she leads efforts in designing and executing product development and regulatory stra
Mixed data for Xencor’s SLE drug pharmatimes
October 11, 2018
Xencor’s experimental systemic lupus erythematosus (SLE) drug XmAb5871 has failed to hit its key target in a mid-stage study.
Xencor Earns $10M Amgen Milestone contractpharma
December 06, 2017
Xencor has won a $ 10 million milestone bonus from Amgen
Xencor Appoints Biology VP contractpharma
June 13, 2017
Dr. Clynes has more than 25 years of medical research experience with expertise in immuno-oncology

Previous page 1 2 Next page